HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CSBR

Champions Oncology, Inc.

Healthcare — Biotechnology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

None
$4.98
$-0.03 (-0.51%)

Price History

52-Week Range
Sign in to add CSBR to a watchlist or set price alerts.

Fundamentals

Market Cap$74.47M
P/E Ratio (TTM)-
Forward P/E53.60
EPS (TTM)$-0.08
Dividend Yield-
Profit Margin-1.98%
Revenue Growth12.00%
ROE-29.97%
Debt/Equity113.03
Recommendation None
Analyst Target-
Analysts-
Next Earnings Sep 10, 2026 AMC
Indexes -

Technical Indicators

RSI (14)38.2
Beta0.39
SMA 20$5.84
SMA 40$6.01
52-Week High$8.74
52-Week Low$5.22
50-Day Avg$5.98
200-Day Avg$6.29
Avg Volume9.2K
Volume2.0K

Performance Analysis

NEUTRAL

CSBR presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($5.22), which could present a value opportunity.
~ RSI at 38.2 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 12.0% year-over-year.
- Operating at a loss with -2.0% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 04:13 UTC

Back to Screener Export Report